DR. LORENZO LEGGIO, MD, PHD

Plain English
This review study looked at ways to improve starch-based bioplastics for food packaging by using various additives, called plasticizers, to enhance their strength and barrier properties. It found that different types of plasticizers, like citric acid and certain oils, can significantly influence how well starch works in packaging, helping to make it more effective and environmentally friendly. Understanding these interactions is important to create better, sustainable alternatives to traditional plastics that are often harmful to the environment. Who this helps: This research benefits manufacturers and developers of biodegradable packaging materials, as well as consumers looking for eco-friendly food packaging options.

Plain English
This research studied how men and women react differently to trauma using a mouse model. They found that female mice were more likely to develop PTSD-like symptoms, while male mice showed different brain changes that could influence their resilience. For example, female mice had shorter neuron connections in specific brain areas, while male mice had longer connections. Understanding these differences is important because it can lead to better treatments for PTSD that take sex into account. Who this helps: This helps patients, particularly women at risk for PTSD, and doctors developing targeted therapies.

Plain English
Researchers studied a drug called PF-5190457, which blocks a receptor involved in feeding and alcohol use, in 29 recently abstinent patients with alcohol use disorder (AUD). They found that PF-5190457 reduced levels of a protein called LEAP2 and decreased growth hormone levels immediately after dosing, but levels returned to normal once the drug was washed out. These findings are important because they offer insights into how the body responds to this potential treatment for AUD, highlighting its effects on certain hormones. Who this helps: This benefits patients with alcohol use disorder looking for new treatment options.

Plain English
This study looked at how two gut hormones, glucagon-like peptide-1 (GLP-1) and ghrelin, affect the development of liver disease related to alcohol use. It found that while alcohol increases both ghrelin and GLP-1 hormones, high levels of ghrelin can make GLP-1 less effective, leading to insulin resistance and liver problems in rats. Notably, rats without the ghrelin receptor were more protected from liver disease despite lower GLP-1 levels, suggesting that blocking ghrelin's action could help treat alcohol-associated liver disease. Who this helps: This research benefits patients with alcohol-related liver issues and potentially guides doctors in developing treatment approaches.

Plain English
This study looked at how changes in a DNA strand can make silver nanoclusters, which are tiny particles, more stable. Researchers found that certain mutations in the DNA helped maintain the structure of the silver cluster, and they also discovered new ways these clusters are packed together. This research is important because it offers insights that could improve the design of nanomaterials used in medical and technological applications. Who this helps: This helps researchers and manufacturers working with nanomaterials.

Plain English
This study looked into how a protein called insulin-like growth factor 2 (IGF2) in sperm affects the early development of embryos, especially for couples undergoing assisted reproductive technology (ART). Researchers found that higher levels of sperm IGF2 were linked to better sperm recovery rates and influenced the timing of early embryo formation, with a significant correlation of 65% (P < 0.001). However, the protein did not seem to impact later stages of embryo growth or the overall success of pregnancies resulting from ART. Who this helps: This research benefits couples facing infertility and those involved in ART.

Plain English
This study looked at new ways to find existing medications that could help treat alcohol use disorder (AUD), a condition that many people struggle with but has limited treatment options. Researchers identified 327 genes related to alcohol use and linked them to 195 FDA-approved drugs, narrowing this down to 26 candidates, including baclofen. They found that patients taking baclofen reduced their alcohol use more effectively than similar patients who didn’t take the drug, showing that repurposing existing medications could lead to better treatment for AUD. Who this helps: Patients with alcohol use disorder.

Plain English
This study looked at how peer support—help from people who have experience with alcohol use disorder (AUD)—can improve care for those with alcohol-associated liver disease (ALD). It found that peer support programs, like Alcoholics Anonymous and newer mobile apps, can help people feel less isolated and more empowered in their recovery. By integrating these supports into medical care, especially for diverse patient groups, we can make a significant difference in their recovery journey. Who this helps: This helps patients with alcohol use disorder and liver disease, as well as their healthcare providers.

Plain English
This study looked at whether a type of medication called glucagon-like peptide-1 receptor agonists (GLP-1RAs) can help people reduce their alcohol consumption. Researchers analyzed health records of over 2,200 adults and found that, on average, those who took GLP-1RAs cut their drinks per week by about 1.81 compared to 1.38 for those who didn’t take the medication. This is important because it shows that GLP-1RAs could be a useful option for people trying to reduce their alcohol intake, especially those who drink less regularly. Who this helps: Patients struggling with alcohol use, particularly those with lower levels of risk.

Plain English
Researchers are looking into the use of GLP-1 therapies, originally designed for obesity and diabetes management, to help people struggling with addiction and mental health issues. Evidence shows that these therapies may reduce drug cravings and consumption, especially for alcohol, nicotine, and opioids; for example, observational studies show that patients receiving GLP-1 treatments had better outcomes related to substance use. Understanding and confirming the potential benefits of GLP-1 therapies in this area is important because it opens new avenues for treating addiction effectively without adding risks to mental health. Who this helps: This benefits patients with addiction issues and their healthcare providers.

Plain English
This study looked at the eating habits and diet quality of people struggling with Alcohol Use Disorder (AUD). Researchers found that, while individuals with AUD generally had a normal Body Mass Index (BMI) and reported consuming enough calories, they often still had nutrient deficiencies because alcohol affects how their bodies absorb and use nutrients. This matters because addressing diet can help improve recovery for those with AUD. Who this helps: This helps patients with Alcohol Use Disorder and their healthcare providers.

Plain English
This study looked at how effective gabapentin and pregabalin are at helping people reduce their alcohol consumption. Researchers found that patients using pregabalin reported a larger decrease in their alcohol use compared to those using gabapentin, especially among individuals with alcohol use disorder (AUD); specifically, the difference for those with AUD was 0.86 points on a standardized scale and 1.74 points for those who binge-drink. This is important because it can guide doctors in choosing the better treatment option for patients struggling with alcohol use. Who this helps: Patients with alcohol use disorder.

Plain English
This study looked at the relationship between prescriptions of GLP-1 receptor agonists (GLP-1RAs) and alcohol consumption among over 393,000 participants in a large health research program. It found that people currently taking GLP-1RAs tended to drink alcohol less frequently, with a 5% lower average alcohol use score compared to those who might receive the medication in the future. This matters because it suggests that GLP-1RAs could help reduce drinking frequency, which might benefit people struggling with alcohol use disorder. Who this helps: Patients with alcohol use disorder.

Plain English
This study focused on a type of enzyme called glucuronoyl esterase (GE) and how it interacts with certain complex sugars found in plant cell walls. The researchers found that the GE named OtCE15A successfully binds to a specific sugar structure called heptasaccharide, which is the largest sugar linked to this type of enzyme studied so far. This is significant because understanding how these enzymes work can help improve industrial processes that use plant materials, making them more efficient. Who this helps: This benefits researchers and industries looking to better utilize plant resources.

Plain English
The British Association for Psychopharmacology reviewed current medications used to treat substance dependence, covering various drugs like alcohol, opioids, and cocaine. They gathered input from experts and created guidelines to help doctors make informed treatment decisions, while also identifying areas where more research is needed. These guidelines aim to standardize care and improve outcomes for people struggling with addiction. Who this helps: This helps patients and healthcare providers involved in addiction treatment.

Plain English
This study looked at patterns of prescribing GLP-1 receptor agonists (GLP-1RAs), which are medications commonly used for type 2 diabetes, obesity, and sleep apnea, among a large group of participants in a research program. Researchers found that out of 15,477 participants who received these prescriptions, the group was older and had more health issues compared to the general study population, highlighting a growing trend in GLP-1RA usage since 2014. This matters because it provides valuable insights into how these medications are being used in real life, which can guide future research and treatment strategies. Who this helps: This benefits patients who use GLP-1RAs and healthcare providers aiming to understand their effectiveness and usage trends.

Plain English
This research explored ways to find new treatments for alcohol use disorder (AUD) by looking at genetic data and health records. The study identified 327 genes related to alcohol consumption and connected them to 195 drugs already approved for other uses, ultimately narrowing it down to 26 promising drugs. Specifically, they found that patients taking the drug baclofen reduced their alcohol intake more than similar patients not taking the drug. Who this helps: This benefits patients struggling with alcohol use disorder by potentially providing them with more effective treatment options.

Plain English
This study looked at two medications, baclofen and acamprosate, used to help people with liver disease related to alcohol use. It found that after one year, 34.3% of patients taking baclofen experienced serious liver issues, compared to 27.4% of those on acamprosate. This is important because it reveals that baclofen may pose a higher risk of liver complications, particularly hepatic encephalopathy, especially for older patients aged 56 to 70. Who this helps: This information benefits doctors treating patients with alcohol-related liver disease.

Plain English
This study looked at whether a type of medication (calcium channel blockers that can enter the brain) helps reduce alcohol consumption in people with alcohol use disorder. Researchers analyzed data from two large health systems and found that starting these medications did not lead to any significant decrease in the number of drinks consumed per week compared to other medications or no treatment at all. This is important because it indicates that these specific medications are not effective for treating alcohol use disorder, suggesting that other treatment options need to be explored. Who this helps: This helps patients struggling with alcohol use disorder by guiding them and their doctors towards more effective treatment options.

Plain English
This study looked at how bariatric surgery (weight loss surgery) affects people's use of alcohol and other substances before and after the surgery. Researchers found that after the surgery, participants reported less problematic use of alcohol and drugs like opioids, amphetamines, and cannabis, but they also felt more guilt about their substance use. Overall, those who had bariatric surgery showed decreased problematic nicotine use compared to those who didn't have the surgery. Who this helps: This study benefits patients considering bariatric surgery who are concerned about substance use.

Plain English
This research examined the worldwide impact of alcohol use disorder (AUD), alcohol-related liver disease (ALD), and liver cancer linked to alcohol between 2000 and 2021. It found that in 2021, there were 111 million cases of AUD, 3 million cases of ALD, and over 132,000 cases of alcohol-related liver cancer. Most concerning is that, while the rates of AUD and ALD decreased slightly, the rate of liver cancer related to alcohol dramatically rose by about 94% during this time, especially among women, highlighting an urgent need for prevention strategies. Who this helps: This helps patients, especially women at risk for alcohol-related liver issues and healthcare providers working to address these problems.

Plain English
This study looked at how drinking alcohol and experiencing childhood trauma affect specific immune proteins in people with Alcohol Use Disorder (AUD). The researchers found that higher alcohol consumption was linked to increased levels of immunoglobulin A (IgA), while childhood trauma was linked to lower levels of immunoglobulin G (IgG). These findings are important because they show how both heavy drinking and past trauma can impact the immune system, possibly leading to health problems like liver disease and other immune issues. Who this helps: This benefits patients with Alcohol Use Disorder and healthcare providers treating them.

Plain English
This study looked at two types of medications: glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4Is) to see how they affect alcohol consumption. The findings showed that people taking GLP-1RAs reduced their alcohol intake more significantly than those not taking any medication (0.09 decrease in drinking scores) and more than those on DPP-4Is (0.11 decrease). Importantly, those with existing alcohol use disorder showed even larger reductions, with a score difference of 0.51 against unmedicated individuals. This matters because it indicates that GLP-1RAs could be effective in helping people with alcohol problems, potentially offering a new treatment option. Who this helps: This helps patients struggling with alcohol use disorder.

Plain English
This research studied how combining medication and therapy affects people with alcohol use disorder (AUD). The results showed that this combination likely reduces the number of heavy drinkers by about 10% and increases the chances of participants staying abstinent by 5%. One reason this matters is that many individuals don’t respond well to either treatment alone, so using both together could improve recovery outcomes. Who this helps: Patients struggling with alcohol use disorder.

Plain English
This research looks at how certain public health policies can help prevent alcohol-associated liver disease (ALD), which is a major health issue worldwide. It highlights that by implementing measures like setting a minimum price for alcohol and restricting alcohol advertising, we can reduce alcohol availability and protect people at risk, ultimately improving liver health and survival rates. For example, these policies can lower the rates of serious liver issues like cirrhosis. Who this helps: This benefits patients at risk for liver disease, healthcare providers, and public health officials.

Plain English
This study looked at how two systems in the brain, one involving CRF and the other involving ghrelin, affect binge drinking behavior in mice. They found that a specific CRF blocker (R121919) increased ghrelin levels and also reduced the binge drinking behavior, while another blocker (astressin) did not have the same effects. Importantly, targeting these systems separately shows promise for reducing binge drinking, suggesting that focusing on the ghrelin receptor might be crucial. Who this helps: This research benefits patients with alcohol use disorder and healthcare providers treating binge drinking.

Plain English
This study looked at the genetic links between alcohol use disorder (AUD) and body mass index (BMI). Researchers found that while there is a significant overlap in 82.2% of the genetics involved, the overall genetic correlation is very low at -0.03, meaning that the genetic factors influence these two issues in different ways. Identifying 132 specific genetic markers that are shared between AUD and BMI helps clarify how they are connected in the brain, particularly in areas related to decision-making and reward. Who this helps: This helps researchers and healthcare providers understand the genetic factors affecting patients with alcohol use disorder and obesity.

Plain English
This study looked at how treating alcohol use disorder (AUD) affects patients with alcohol-related liver disease (ALD), focusing on their chances of relapsing into drinking and other health outcomes. The analysis of nearly 94,000 patients found that treatment significantly reduces alcohol relapse by 73% overall and even more, by 77%, when medication is used. For patients who had received liver transplants, treatment cut the risk of relapse by 59% and decreased mortality from 56% in some cases. Who this helps: This research benefits patients struggling with alcohol use disorder and liver disease, as well as the doctors treating them.

Plain English
This study looked at the blood of three groups of people: healthy individuals, those with alcohol use disorder (AUD) who are currently drinking, and those with AUD who have been abstinent for at least six weeks and are seeking treatment. Researchers found that the levels of certain immune and hormone markers in abstinent individuals were different from healthy individuals; specifically, IL-8 was higher, while BDNF was lower in abstinent individuals compared to healthy controls. Understanding these differences is important for improving treatment strategies for those recovering from alcohol dependence. Who this helps: This research benefits patients recovering from alcohol use disorder and their doctors.

Plain English
This study examined how certain substances, specifically salts and citrate, affect the activity of an enzyme called LsAA9A, which helps break down tough carbohydrates like cellulose. Researchers found that high concentrations of chloride and similar salts significantly reduced the enzyme's activity—even though chloride usually helps it bind to its target. In addition, citrate was found to completely block the enzyme from accessing its carbohydrate targets. Who this helps: This research helps scientists and researchers working on enzyme applications in biofuels and waste management.

Plain English
Researchers studied new medications for treating obesity, finding that some can lead to significant weight loss of 15% to 20%. These treatments not only help people lose weight but also improve heart health and may benefit those with other medical issues like addiction. This is important because it highlights innovative ways to tackle obesity and the social and economic challenges that come with it, including unequal access to treatment for both adults and children. Who this helps: Patients struggling with obesity and related health conditions.

Plain English
This study looked at how drinking habits affect heart health in people who drink alcohol, dividing them into high-risk and low-risk groups. The researchers found that people who drank heavily had higher blood pressure and heart rates, making them more likely to have alcohol use issues. In fact, having higher mean arterial pressure and heart rates increased the chances of being labeled as a high-risk drinker, while some heart measures were linked to lower-risk drinking. Who this helps: This research benefits patients with alcohol misuse and healthcare providers by helping identify those at risk earlier.

Plain English
This study looked at the eating habits of people with alcohol use disorder (AUD) compared to healthy individuals, focusing on their consumption of ultraprocessed foods, added sugars, and overall diet quality. It found that all groups had similar poor diets, with over 55% of their food coming from ultraprocessed sources and more than 8% of their energy from added sugars. The newly abstinent individuals showed some links between their diet and cardiovascular disease risk, highlighting the need for better nutrition support for those recovering from alcohol use disorder. Who this helps: This benefits patients recovering from alcohol use disorder by emphasizing the importance of healthy eating.

Plain English
This study looked at how cravings for cocaine and actual use change during treatment for cocaine addiction. Researchers analyzed data from over 1,000 participants and identified three groups based on their craving and use patterns: one group had high cravings and high use (40%), another had decreasing cravings but still high use (36.8%), and the last group showed decreasing cravings and decreasing use (23.2%). The group with decreasing cravings and use improved significantly in areas like drug and alcohol use, mental health, and relationships compared to the others, particularly those treated with modafinil, who were more likely to show this improvement. Who this helps: This research benefits patients with cocaine use disorder and their healthcare providers.

Plain English
This study looked at how new treatments could help people with alcohol and other substance use disorders (ASUDs). Researchers found that hormones related to feeding and stress in the body affect how addictive substances work in the brain, which could lead to new medications to treat these conditions. Currently, there are very few approved drug treatments for substances other than alcohol, tobacco, and opioids, highlighting the urgent need for new options to help many people struggling with addiction. Who this helps: This helps patients battling substance use disorders and the healthcare professionals treating them.

Plain English
This study focused on metabolic and alcohol-related liver disease (MetALD), which involves the effects of metabolism and alcohol on the liver. Researchers found that using non-invasive tests and measuring factors like alcohol intake can help improve clinical trials, making it easier to evaluate treatments. These advancements are important because they may speed up the development of new drugs and lead to better care for patients with this condition. Who this helps: Patients with metabolic and alcohol-related liver disease.

Plain English
This study looked at how certain proteins found in tiny particles released by cells (called extracellular vesicles) can help predict if colorectal cancer patients will have their disease come back after treatment. The researchers used advanced imaging techniques to find that specific combinations of these proteins could reliably tell the difference between patients who would experience a recurrence and those who wouldn't. The results are significant because they show a promising, less invasive way to monitor cancer patients, with a 20-30% recurrence rate within 5 years. Who this helps: This helps colorectal cancer patients and their doctors monitor disease recurrence more safely and effectively.

Plain English
This research paper explores the connections between alcohol use disorder (AUD) and obesity, noting that both conditions can harm the liver and heart in similar ways. The review gathered various studies that highlight how some treatments for obesity, particularly drugs targeting gut hormones like GLP-1, might also be effective for treating AUD. Understanding how these two issues relate can lead to better treatment options for individuals facing both alcohol and weight problems. Who this helps: This benefits patients struggling with both alcohol use disorder and obesity, as well as doctors looking for effective treatment strategies.

Plain English
This research paper looks at a method called the alcohol cue-exposure paradigm, which helps scientists study alcohol use disorder (AUD) and improve treatments for it. The authors found that while this method has proved useful in understanding cravings and developing medications, there's a need to improve the way it is used in studies to speed up creating new treatments. Making these changes could lead to faster approval of better medications for people struggling with AUD. Who this helps: Patients with alcohol use disorder.

Plain English
This study looked at how two motivational systems, called the Behavioral Inhibition System (BIS) and the Behavioral Approach System (BAS), affect people with Alcohol Use Disorder (AUD). Researchers found that higher BIS scores were linked to more severe alcohol use and obsessive drinking behaviors, while anxiety and depression played a role in this connection. Specifically, people with higher BIS scores had worse outcomes on tests measuring their alcohol use and compulsive drinking, indicating that emotional factors like anxiety and depression can worsen alcohol-related problems. Who this helps: This helps patients with Alcohol Use Disorder by highlighting the importance of addressing anxiety and depression in their treatment.

Plain English
This study explored how GLP-1 receptor agonists, which are medications used primarily for diabetes and weight loss, may also help with overeating and substance use disorders like binge eating and alcohol use. The findings suggest these drugs work in both the body and the brain, which could lead to effective treatments for these conditions. This is important because it opens new pathways for managing behaviors that contribute to obesity and addiction, with the potential for broader applications in mental health. Who this helps: This helps patients struggling with obesity and substance use disorders.

Plain English
This study looked at the levels of a substance called lipocalin-2 (LCN2) in the blood of rats with alcohol dependence and in people with alcohol use disorder (AUD) after drinking alcohol. The researchers found that in rats, LCN2 levels changed with the time of day but not due to chronic alcohol exposure, and for people with AUD, alcohol intake didn't affect LCN2 levels either. These findings indicate that while LCN2 may play a role in daily body rhythms, it doesn’t seem to be influenced by alcohol, which is important for understanding its potential role in AUD treatment. Who this helps: This helps researchers and healthcare providers working with patients who have alcohol use disorder.

Plain English
This study focuses on a new category of liver disease called metabolic dysfunction and alcohol-associated liver disease (MetALD), which affects people who are overweight or have diabetes and drink moderate to high amounts of alcohol—specifically 140-350 grams per week for women and 210-420 grams for men. It found that MetALD shows various symptoms and severity based on individual health profiles and drinking habits, and both alcohol use and metabolic issues can combine to worsen liver damage. Understanding MetALD is crucial because as more people are affected by obesity and alcohol consumption, we need better ways to identify and treat this condition. Who this helps: This benefits patients with liver disease and their doctors by guiding better diagnosis and treatment options.

Plain English
This study looks at how GLP-1 receptor agonists, which are medications currently used for conditions like diabetes and obesity, might also help treat alcohol and substance use disorders. The researchers found that GLP-1RAs could interact with the brain's pathways related to addiction, making them a promising option for new treatments. This is important because effective treatments for these disorders are limited, and new options could improve health and recovery for many individuals. Who this helps: This helps patients struggling with alcohol and substance use disorders.

Plain English
This study looked at how alcohol use disorder (AUD) affects health, particularly liver disease, and explored ways to improve care for patients. Researchers found that many doctors aren't properly assessing alcohol use due to various challenges, but using tools like standardized questionnaires and biological markers can help identify at-risk individuals. Effective treatments that don't involve medication, such as therapy and support groups, work for all patients, even those with severe liver damage, and care should involve multiple healthcare specialists. Who this helps: This benefits patients with alcohol use disorder and liver disease, as well as their healthcare providers.

Plain English
This study looked at whether a drug called PF-5190457, which blocks a receptor linked to hunger and cravings, could help people with alcohol use disorder (AUD) by reducing their cravings for alcohol. Researchers found that while the drug did not reduce alcohol cravings when participants were shown alcohol-related cues, it did lower the number of virtual calories people selected in a virtual reality food task (with a significant result of P = 0.04). These findings show that blocking this receptor might influence food choices but not alcohol cravings, indicating more research is needed on how this system interacts with AUD. Who this helps: This helps patients with alcohol use disorder.